This study was carried out to prove the effects of KSYT on the hematopoiesis of bone marrow cell, proliferation of splenic cell, to administration with cyclophosphamide (100㎎/㎏) in C57BL/6 mice, and on the expressing thrombopoietin(TPO), stem cell factor(SCF) and interleukin-3 of bone marrow cell, interleukin-10(IL-10), interferon-γ (INF-γ) of splenic cell, active NOs change of macrophage in continuous medication KSYT, detected in serial sections using the reverse transcriptase in Situ PCR technique. Splenic cells were analyzed using flow cytometry. Two-color staining was performed with FITC-leveled CD4^+, CD8^+ and CD19^+ for leucocytes.
The result were obtained as follows ;
1. The cytotoxicity of L+14 fibroblast cell in the KSYT treatment was no significant differences than in the negative control data.
2. After CTX treatment, the total WBC, RBC and PLT count was increased in the KSYT administration group than in the control group.
3. After CTX treatment, the proliferation of splenic leucocyte was increased 2∼3-folds in the KSYT administration group than in the control group.
4. After CTX treatment, the expressing TPO, SCF and IL-3 of bone marrow cell was increased in the KSYT administration group than in the negative control group.
5. Proliferation on the immune function, hemagglutinin and hemolysin titer was increased in the KSYT administration group than in the normal control group.
6. The suppressor/cytotoxic cell, helper/inducer, cell and B cell was increased numbers CD4´ and CD8´ cells in the KSYT administration group than in the normal control group.
7. After KSYT administration for 10 days, the expressing IL-10 of splenic leucocytes was inhibited than in the normal control group.
8. After KSYT administration for 10 days, the expressing IFN-γ of splenic leucocytes was increased 5-folds than in the normal control group.
9. After KSYT administration for 10 days, products of NO quality and expressing of NOs Ⅱ in macrophage was increased than in the normal control group.
10. After KSYT administration for 10 days, the number of survival mice with EMC virus infection was long survived than in the normal control group.
This data suggests that KSYT may be improving the hematopoiesis of activate bone marrow cell and the immune function of immune splenic cell in mice.
|